Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

The signal transducers and activators of transcription (STAT)factors function as downstream effectors of cytokine and growth factor receptor signaling. Compared with normal cells and tissues, constitutively activated STATs have been detected in a wide variety of human cancer cell lines and primary tumors. STATs are activated by tyrosine phosphorylation, which is normally a transient and tightly regulated process. In tumor cells, constitutive activation of STATs is linked to persistent activity of tyrosine kinases, including Src, epidermal growth factor receptor, Janus kinases, Bcr-Abl, and many others. Such oncogenic tyrosine kinases are often activated as a consequence of permanent ligand/receptor engagement in autocrine or paracrine cytokine and growth factor signaling or represent autonomous constitutively active enzymes as a result of genetic alterations found in tumor but not normal cells. Persistent signaling of specific STATs, in particular Stat3 and Stat5, has been demonstrated to directly contribute to oncogenesis by stimulating cell proliferation and preventing apoptosis. STATs participate in oncogenesis through up-regulation of genes encoding apoptosis inhibitors and cell cycle regulators such as Bcl-x(L), Mcl-1, cyclins D1/D2, and c-Myc. Inhibition of constitutively active STAT signaling pathways has been shown repeatedly to inhibit tumor cell growth in vitro and in vivo and provides a novel means for therapeutic intervention in human cancer. In this review, we will: (a) explain the mechanisms of STAT activation in normal and malignant signaling; (b) summarize recent evidence for the critical role of constitutively activated Stat3 and Stat5 in oncogenesis; (c) identify candidate STAT target genes implicated in tumor progression; and (d) discuss molecular and pharmacological strategies to interfere with STAT signaling for potential therapeutic intervention in human cancer.

[1]  L. Hennighausen,et al.  Distinctive Roles of STAT5a and STAT5b in Sexual Dimorphism of Hepatic P450 Gene Expression , 1999, The Journal of Biological Chemistry.

[2]  J. Ihle.  The Stat family in cytokine signaling. , 2001, Current opinion in cell biology.

[3]  B. Chait,et al.  DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2‐terminal domains stabilizes binding of two dimers to tandem DNA sites. , 1996, The EMBO journal.

[4]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[5]  T. Decker,et al.  Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins , 1999, Cellular and Molecular Life Sciences CMLS.

[6]  N. Danial,et al.  Jak-STAT signaling induced by the v-abl oncogene. , 1995, Science.

[7]  D. Hilton,et al.  Negative regulation of the JAK/STAT pathway , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[8]  P Jay,et al.  Specific inhibition of Stat3 signal transduction by PIAS3. , 1997, Science.

[9]  J. Turkson,et al.  Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling , 2000, Oncogene.

[10]  T. Yeatman,et al.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Lamb,et al.  Pharmaceutical intervention in the JAK/STAT signaling pathway , 2000, Oncogene.

[12]  R. Jove,et al.  Cooperative Regulation of Mcl-1 by Janus Kinase/STAT and Phosphatidylinositol 3-Kinase Contribute to Granulocyte-Macrophage Colony-Stimulating Factor-Delayed Apoptosis in Human Neutrophils1 , 2001, The Journal of Immunology.

[13]  J. Darnell,et al.  Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA , 1998, Cell.

[14]  J. Darnell,et al.  Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway , 1995, Science.

[15]  J. Griffin,et al.  Bcr/Abl activates transcription of the Bcl-X gene through STAT5. , 2000, Blood.

[16]  J. Turkson,et al.  Requirement for Ras/Rac1-Mediated p38 and c-Jun N-Terminal Kinase Signaling in Stat3 Transcriptional Activity Induced by the Src Oncoprotein , 1999, Molecular and Cellular Biology.

[17]  D. Levy,et al.  Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease , 1996, Cell.

[18]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Turkson,et al.  STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.

[20]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[21]  D. Levy,et al.  Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice , 2000, Oncogene.

[22]  W. Leonard,et al.  The role of Stat5a and Stat5b in signaling by IL-2 family cytokines , 2000, Oncogene.

[23]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[24]  S. Akira,et al.  Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.

[25]  R. Jove,et al.  Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[26]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[27]  R. Jove,et al.  Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. , 1998, Journal of biomedical science.

[28]  J. Grandis,et al.  STAT signaling in head and neck cancer , 2000, Oncogene.

[29]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Lammers,et al.  STAT3β, a Splice Variant of Transcription Factor STAT3, Is a Dominant Negative Regulator of Transcription* , 1996, The Journal of Biological Chemistry.

[31]  O. Jänne,et al.  Androgen-receptor-interacting nuclear proteins. , 2000, Biochemical Society transactions.

[32]  N. Perrimon,et al.  The roles of the Drosophila JAK/STAT pathway , 2000, Oncogene.

[33]  K. Shuai,et al.  Modulation of STAT signaling by STAT-interacting proteins , 2000, Oncogene.

[34]  R. Jove,et al.  STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. , 1999, Blood.

[35]  J. Darnell,et al.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.

[36]  Matthew B. Wilson,et al.  Control of myeloid differentiation and survival by Stats , 2000, Oncogene.

[37]  J. Ihle.  Hematopoietic Signaling by the Cytokine Receptor Superfamily , 1995 .

[38]  Pavel Kovarik,et al.  Serine phosphorylation of STATs , 2000, Oncogene.

[39]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[40]  D. Hilton,et al.  Negative regulation of cytokine signaling , 2001, Journal of leukocyte biology.

[41]  S. Rane,et al.  IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled , 2000, Oncogene.

[42]  J. Ihle,et al.  Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. , 1999, Immunity.

[43]  A. Mui,et al.  The role of STATs in proliferation, differentiation, and apoptosis , 1999, Cellular and Molecular Life Sciences CMLS.

[44]  R. Schreiber,et al.  Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway , 1996, Cell.

[45]  Mikhail Chernov,et al.  Regulation of c‐myc expression by IFN‐γ through Stat1‐dependent and ‐independent pathways , 2000 .

[46]  N. Copeland,et al.  Distribution of the mammalian Stat gene family in mouse chromosomes. , 1995, Genomics.

[47]  D. Levy,et al.  Physiological significance of STAT proteins: investigations through gene disruption in vivo , 1999, Cellular and Molecular Life Sciences CMLS.

[48]  N. Danial,et al.  JAK-STAT signaling activated by Abl oncogenes , 2000, Oncogene.

[49]  R. Craig,et al.  Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. , 1997, Blood.

[50]  B. Nelson,et al.  The IL-2 Receptor Promotes Lymphocyte Proliferation and Induction of the c-myc, bcl-2, and bcl-x Genes Through the trans-Activation Domain of Stat51 , 2000, The Journal of Immunology.

[51]  Hua Yu,et al.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.

[52]  C. Schindler,et al.  Interferons as a paradigm for cytokine signal transduction , 1999, Cellular and Molecular Life Sciences CMLS.

[53]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[54]  T. Hirano,et al.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.

[55]  Michael P. Brown,et al.  Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in Cytokine Responses , 1998, Cell.

[56]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[57]  S. Akira.  Roles of STAT3 defined by tissue-specific gene targeting , 2000, Oncogene.

[58]  J. Darnell,et al.  Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions , 1994, Cell.

[59]  J. Griffin,et al.  STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. , 2000, Blood.

[60]  J. Turkson,et al.  Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation* , 2001, The Journal of Biological Chemistry.

[61]  J. Darnell,et al.  The Significance of Tetramerization in Promoter Recruitment by Stat5 , 1999, Molecular and Cellular Biology.

[62]  H. Lodish,et al.  Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice A Direct Role for Stat5 in Bcl-XL Induction , 1999, Cell.

[63]  R. Jove,et al.  Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.

[64]  K. Cowan,et al.  Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  Y. Tan,et al.  Activation and association of Stat3 with Src in v-Src-transformed cell lines , 1996, Molecular and cellular biology.

[66]  Thomas S. Lin,et al.  STAT signaling in the pathogenesis and treatment of leukemias , 2000, Oncogene.

[67]  G. Daley,et al.  Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[68]  B. Nelson,et al.  Stat5 and Sp1 Regulate Transcription of the Cyclin D2 Gene in Response to IL-21 , 2001, The Journal of Immunology.

[69]  H. Pendeville,et al.  SOCS3 Is Essential in the Regulation of Fetal Liver Erythropoiesis , 1999, Cell.

[70]  H. Kantarjian,et al.  Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. , 2001, Blood.

[71]  Takashi Tanaka,et al.  The biology of Stat4 and Stat6 , 2000, Oncogene.

[72]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[73]  C. Sawyers,et al.  Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. , 1996, Oncogene.

[74]  B. Groner,et al.  Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. , 1995, The EMBO journal.

[75]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[76]  Bernd Groner,et al.  TRANSCRIPTION FACTOR STAT3B/DNA COMPLEX , 1999 .

[77]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[78]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[79]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[80]  D. Levy,et al.  FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. , 1999, Genes & development.

[81]  S. Akira,et al.  Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. , 1999, Genes & development.

[82]  P. Coffer,et al.  The role of STATs in myeloid differentiation and leukemia , 2000, Oncogene.

[83]  B. Calabretta,et al.  Signal Transducer and Activator of  Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis , 1999, The Journal of Experimental Medicine.

[84]  J. Gibbs.  Mechanism-based target identification and drug discovery in cancer research. , 2000, Science.

[85]  R. Jove,et al.  STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. , 1999, Current opinion in oncology.

[86]  L. Hennighausen,et al.  Stat5a is mandatory for adult mammary gland development and lactogenesis. , 1997, Genes & development.

[87]  J E Darnell,et al.  A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[88]  M. McMahon,et al.  Identification and Characterization of a Constitutively Active STAT5 Mutant That Promotes Cell Proliferation , 2022 .

[89]  S. Pestka,et al.  Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes , 2000, Oncogene.

[90]  J. Ihle,et al.  Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. , 1999, Immunity.

[91]  G. Stark,et al.  Complex roles of Stat1 in regulating gene expression , 2000, Oncogene.

[92]  O. Witte,et al.  BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner , 1991, Cell.

[93]  J. Darnell.  Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[94]  J. Schneider-Mergener,et al.  Mutational analysis of acute-phase response factor/Stat3 activation and dimerization , 1997, Molecular and cellular biology.

[95]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[96]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[97]  J. Ihle.  Cytokine receptor signalling , 1995, Nature.

[98]  E. Reddy,et al.  Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs , 1997, Molecular and cellular biology.

[99]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[100]  C. Dearolf.  JAKs and STATs in invertebrate model organisms , 1999, Cellular and Molecular Life Sciences CMLS.

[101]  J. Kutok,et al.  Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation , 2001, Molecular and Cellular Biology.

[102]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[103]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[104]  J. Schwartz,et al.  The role of STAT proteins in growth hormone signaling , 2000, Oncogene.

[105]  S. Becker,et al.  Three-dimensional structure of the Stat3β homodimer bound to DNA , 1998, Nature.

[106]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[107]  K. Shuai,et al.  Distinct roles of the NH2- and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[108]  W. Farrar,et al.  Activation of Estrogen Receptor Blocks Interleukin-6-inducible Cell Growth of Human Multiple Myeloma Involving Molecular Cross-talk between Estrogen Receptor and STAT3 Mediated by Co-regulator PIAS3* , 2001, The Journal of Biological Chemistry.

[109]  Alexander Levitzki,et al.  Protein tyrosine kinase inhibitors as novel therapeutic agents. , 1999, Pharmacology & therapeutics.

[110]  D. Chang,et al.  Inhibition of Stat1-mediated gene activation by PIAS1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[111]  A. Yoshimura,et al.  The JAK‐binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop , 1999, The EMBO journal.

[112]  M. Emi,et al.  Localization of a Target Region of Allelic Loss to a 1‐cM Interval on Chromosome 16p.13.13 in Hepatocellular Carcinoma , 1999, Japanese journal of cancer research : Gann.

[113]  W. Leonard,et al.  Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. , 1995, Science.

[114]  R. Jove,et al.  Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. , 2001, Cancer research.

[115]  Levy De,et al.  Physiological significance of STAT proteins: investigations through gene disruption in vivo. , 1999 .

[116]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.